Belite Bio, Inc (BLTE) stock
BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 5/30
$157.72−4.84 (-2.98%)
Close on Nov 17, 2026Market cap $6.20BP/E –Yield –
Belite Bio r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $45.38M, up 51.6% from the year before. The highest annual figure on record is $45.38M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.38M | +51.6% |
| FY2024 | Dec 31, 2024 | $29.94M | +20.5% |
| FY2023 | Dec 31, 2023 | $24.84M | +180.1% |
| FY2022 | Dec 31, 2022 | $8.87M | +19.5% |
| FY2021 | Dec 31, 2021 | $7.42M | +101.2% |
| FY2020 | Dec 31, 2020 | $3.69M | – |
See a number that looks wrong?